Details of Disease

General Information of Disease (ID: DISQZRON)

• Disease Name: Coronavirus infection
• Disease Class: 1D92: Coronavirus infection
• Definition: Virus diseases caused by the coronavirus genus. Some specifics include transmissible enteritis of turkeys (enteritis, transmissible, of turkeys); feline infectious peritonitis; and transmissible gastroenteritis of swine (gastroenteritis, transmissible, of swine).
• Disease Hierarchy:
  DISEYYZZ: Coronaviridae infectious disease
  DISEM33Q: Infectious disease
  DISQZRON: Coronavirus infection
• ICD Code:
  ICD-11: ICD-11: 1D92
  ICD-10: ICD-10: B34.2
  Expand ICD-11: '1D92
  Expand ICD-10: 'B34.2
• Disease Identifiers:
  MONDO ID: MONDO_0005719
  MESH ID: D018352
  MedGen ID: 61674
  SNOMED CT ID: 186747009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
VRX496	DMIO4V5	Approved	Antisense drug	[1]

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CX-4945	DMWE7B9	Phase 2	Small molecular drug	[2]
D-3252	DMHGMTZ	Phase 1	NA	[3]
GLS-5300	DMF1DP3	Phase 1	NA	[4]
REGN3048	DM0E3ZG	Phase 1	Antibody	[5]
REGN3051	DM7LIV2	Phase 1	Antibody	[5]
VRC-SRSDNA015-00-VP	DMI1262	Phase 1	NA	[6]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID27998201-Compound-1	DM5QH4C	Patented	Small molecular drug	[7]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aloxistatin	DMGW07M	Discontinued in Phase 3	Small molecular drug	[8]

This Disease is Treated as An Indication in 9 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
5-(N,N-hexamethylene)-amiloride	DMC4IUQ	Preclinical	Small molecular drug	[8]
DecRVKRCMK	DMAUILH	Preclinical	Small molecular drug	[8]
GRL001	DM19T2V	Preclinical	Small molecular drug	[8]
GRL0617	DMX9AGF	Preclinical	Small molecular drug	[8]
LJ001	DMROKKZ	Preclinical	Small molecular drug	[8]
m337	DM7HUVB	Preclinical	Antibody	[8]
MERS-27	DMVGIB4	Preclinical	Antibody	[8]
MERS-4	DMS6KT8	Preclinical	Antibody	[8]
PJ34	DMXO6YH	Preclinical	Small molecular drug	[8]

This Disease is Treated as An Indication in 1 Preclinical Drugs

Drug Name	Drug ID	Highest Status	Drug Type	REF
SSYA10-001	DM0NPIO	Preclinical	Small molecular drug	[8]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DW-941	DMUMA36	Investigative	NA	[9]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT00246610) Safety Of VIRACEPT 625mg Administered To HIV-Infected Women During Pregnancy. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04668209) Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) (CX4945). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Protein Sciences Corporation.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT00099463) Phase I Study of a Vaccine for Severe Acute Respiratory Syndrome (SARS). U.S. National Institutes of Health.
• [7] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [8] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
• [9] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.